郑煤机(00564.HK)控股股东转让16%股份完成过户登记
郑煤机(00564.HK)公布,公司收到河南装备集团发来的由中国证券登记结算有限责任公司出具的《过户登记确认书》,河南装备集团向泓羿投资协议转让公司16%的股份已经完成过户登记。
是次股份转让完成後,河南装备集团持有公司2.44亿股股份,占公司总股的14.08%;泓羿投资持有公司2.78亿股股份,占公司总股的16%,同时其一致行动人河南资产持有公司6,920.92万股股份,占公司总股的3.99%,泓羿投资与河南资产合计持有郑煤机19.99%股份,根据泓羿投资与河南资产签署的《一致行动协议书》以及泓羿投资的治理结构,本次股份转让完成後泓羿投资和河南资产成为公司的控股股东,公司无实际控制人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.